Qiagen NVXTER:QIA +4.28%69 Operating Margin % is 23.69% as of Mar. 2026, which is 10% above its 10-year median of 21.61. GuruFocus rates XTER:QIA with a GF Score™ of 69/100 and a GF Value™ of €46.28 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Qiagen NV ranks better than 92.65% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Qiagen NV's Operating Income for the
three
months ended in Mar. 2026 was €101 Mil. Qiagen NV's Revenue for the
three
months ended in Mar. 2026 was €426 Mil. Therefore, Qiagen NV's Operating Margin % for the quarter that ended in Mar. 2026 was 23.69%.
Warning Sign:
Qiagen NV operating margin has been in a 5-year decline. The average rate of decline per year is -11%.
The historical rank and industry rank for Qiagen NV's Operating Margin % or its related term are showing as below:
XTER:QIA'
s Operating Margin % Range Over the Past 10 Years
Min: 7.39 Med: 21.61 Max: 29.22
Current: 24.38
XTER:QIA's Operating Margin % is ranked better than 92.65% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.195
vs XTER:QIA: 24.38
Qiagen NV's 5-Year Average Operating Margin % Growth Rate was -11.00% per year.
Qiagen NV's Operating Income for the
three
months ended in Mar. 2026 was €101 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €440 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Qiagen NV Operating Margin % Related Terms
Qiagen NV Operating Margin % Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs CRL, ICLR, BLLN: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Qiagen NV's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Qiagen NV's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Qiagen NV's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a Operating Margin % of 23.69% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Qiagen NV and its competitors. This is 10% above median its historical median of 21.61. Over the past decade, Qiagen NV's Operating Margin % has ranged from 7.39 to 29.22. According to the industry distribution chart, Qiagen NV ranks #15 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 7.4%.
Is Qiagen NV's Operating Margin % too high?
Qiagen NV's current Operating Margin % of 23.69% is 10% above median its 10-year median of 21.61. Over the past 10 years, this metric has ranged from a low of 7.39 to a high of 29.22. Based on the distribution chart, Qiagen NV ranks #15 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Operating Margin % compare to CRL and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #15 out of 204 companies for Operating Margin %. This places Qiagen NV in the top 7% of its industry — outperforming the majority of peers. Historically, Qiagen NV's own Operating Margin % has ranged from 7.39 to 29.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Qiagen NV and its competitors. Qiagen NV's current Operating Margin % is 23.69%, which is 10% above median its own 10-year median of 21.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €46.28, compared to a current price of €34.01 — trading 26.5% below its estimated fair value. The current Operating Margin % is 23.69%, which is 10% above median its 10-year median of 21.61. Qiagen NV's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Operating Margin % is 23.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.01 is trading 26.5% below its estimated GF Value™ of €46.28.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
Operating Margin %: 23.69% (10% above median its 10-year median of 21.61)
GF Value™: €46.28 vs. price of €34.01 (26.5% below fair value)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
69GF Score
Get the complete analysis for XTER:QIA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
